BCL2 and acute myeloid leukemia: In 2018, the Bcl-2 inhibitor venetoclax has been added to hypomethylating agents or low-dose cytarabine for treatment of newly diagnosed AML patients aged 75 or older not eligible for high-dose standard chemotherapy based on phase III clinical trial results (DiNardo CD et al., 2020; Stein EM et al., 2020; Pollyea DA et al., 2021; Labrador J et al., 2022; Mustafa Ali MK et al., 2022; Wolach O et al., 2022).